Volume 94 Issue 47 | p. 15 | Concentrates
Issue Date: November 28, 2016

Celgene acquires a myeloma treatment

Department: Business
Keywords: oncology, Celgene, multiple myeloma, marizomib

Celgene has acquired the proteasome inhibitor marizomib from Triphase Accelerator for an undisclosed sum plus future milestone payments. Triphase has completed Phase I clinical trials of marizomib as a treatment for glioblastoma and multiple myeloma. Celgene already markets the multiple myeloma treatments Revlimid and Thalomid. Triphase, a spin-off from the Ontario Institute for Cancer Research, granted Celgene the option to buy the drug in 2014.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment